FIGARO

What is the Study about?

The purpose of this study is to evaluate whether finerenone is effective and safe in reducing the incidence of cardiovascular events in patients with type 2 diabetes and diabetic kidney disease. Type 2 diabetes is a chronic disease in which the body is unable to properly use insulin, a hormone that regulates blood sugar levels, or does not produce enough insulin, typically leading to increased blood sugar levels and other complications. Along with diabetic kidney disease, cardiovascular disease is a common and major complication affecting patients with type 2 diabetes. This study will look at the number of cardiovascular events in participants with type 2 diabetes and diabetic kidney disease and compare these rates among patients receiving finerenone or placebo.

Eligibility to participate

  • Are between the age of 18 – 70 years
  • Have type 2 diabetes
  • Have diabetic kidney disease

What is involved in the Study?

Participants will be randomly assigned (like the flip of a coin) to receive either finerenone or a placebo and come to the University of Minnesota for 12 visits over 3 years. At these visits medical history will be reviewed, an electrocardiogram (ECG) taken, and blood and urine collected for laboratory testing. Compensation is available.

Principal Investigator

Luiza Caramori, MD, PhD, MSc


For More Information

Birgit Fink
finkx120@umn.edu
(612) 301-2103